Vera Therapeutics VERA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's cash & equivalents?
- Vera Therapeutics (VERA) reported cash & equivalents of $114.35M in Q1 2026.
- How has Vera Therapeutics's cash & equivalents changed year-over-year?
- Vera Therapeutics's cash & equivalents increased by 107.6% year-over-year, from $55.09M to $114.35M.
- What is the long-term trend for Vera Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Vera Therapeutics's cash & equivalents has grown at a 45.7% compound annual growth rate (CAGR), from $54M to $354.73M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.